VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-27.04%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$555M
AUM Growth
+$555M
(-45%)
Cap. Flow
+$74.7M
Cap. Flow
% of AUM
13.45%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| 1 |
Ventyx Biosciences
VTYX
|
$99.5M |
Top Sells
| 1 |
Harmony Biosciences
HRMY
|
$13.8M |
| 2 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
$10.5M |
| 3 |
Akero Therapeutics
AKRO
|
$616K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $208M | 37.55% | 9,699,925 | – | – |
|
|
2
Harmony Biosciences
HRMY
$2.12B
| $117M | 21.05% | 2,740,411 -322,783 | -11% | -$13.8M |
|
|
3
Ventyx Biosciences
VTYX
$171M
| $99.5M | 17.93% | +5,011,536 | New | +$99.5M |
|
|
4
Akero Therapeutics
AKRO
$3.74B
| $45.9M | 8.28% | 2,171,664 -29,114 | -1% | -$616K |
|
5
Pharvaris
PHVS
$1.39B
| $33.1M | 5.97% | 2,303,310 | – | – |
|
|
IMPL
6
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $23.8M | 4.29% | 2,759,791 | – | – |
|
|
ELEV
7
DELISTED
Elevation Oncology
ELEV
| $15.7M | 2.83% | 2,608,167 | – | – |
|
|
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $10.5M | 1.9% | 3,673,374 | – | – |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $1.09M | 0.2% | 161,897 | – | – |
|
|
MTCR
10
DELISTED
Metacrine, Inc. Common Stock
MTCR
| – | – | -3,059,123 | Closed | -$10.5M |
|